Navigation Links
Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, Inc. (NYSE:DNA) today announced updated results from a joint analysis of two Phase III clinical trials studying Herceptin(R) (trastuzumab) for the adjuvant treatment of HER2-positive breast cancer. Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) showed that, with median follow-up of nearly three years, the addition of Herceptin to standard adjuvant therapy significantly improved overall survival in women with HER2-positive, node-positive breast cancer, compared to patients who received standard adjuvant therapy alone. Herceptin (with chemotherapy) is the first and only HER2-targeted therapy to demonstrate an overall survival benefit in adjuvant breast cancer, based on these study results, and in first-line metastatic HER2-positive breast cancer.

"These findings show, when using Herceptin for the adjuvant treatment of women with HER2-positive, node-positive breast cancer, patients live longer," said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. "These data further reinforce the use of Herceptin and chemotherapy as the foundation of care for women with this aggressive form of the disease."

Edith Perez, M.D., director of Mayo Clinic's Multidisciplinary Breast Clinic in Jacksonville, Fla., presented these updated data from the joint analysis of NCCTG N9831 and NSABP B-31 (Abstract #512 -- Monday, June 4, 2007, 9 a.m. CDT) studying Herceptin in the adjuvant setting. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.

These two randomized, controlled Phase III studies evaluated four cycles of doxorubicin and cyclophosphamide followed by paclitaxel, either every t
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
11. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
Post Your Comments:
(Date:8/27/2015)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... featuring the use of ActiPatch®, its novel musculoskeletal pain ... Congress of the European Pain Federation EFIC®, ... The Company will also be exhibiting at the Congress ... , department clinical and experimental rheumatology from the University ...
(Date:8/27/2015)... 2015 The Elekta Linac-based Brain ... Boston on July 9th for its inaugural ... more fully exploit the potential of advances in linear ... "As an established provider of sophisticated cancer ... a leadership role - in collaboration with its clinical ...
(Date:8/27/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 27, ... developing Probody™ therapeutics for the treatment of cancer, ... previously a member of the company,s Board of ... Humphrey formerly led immuno-oncology at Eli Lilly and ... (ipilmumab), the first FDA approved checkpoint inhibitor, at ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... Jones Sustainability Indexes for the Sixth... -- ABBOTT PARK, Ill., Nov. 8, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
... 8, 2010 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Link, a versatile online resource that helps simplify and ... The web-based application gives patients who self-test ... report their test results and gives doctors a single, ...
Cached Medicine Technology:Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 2Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 3Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 4Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 5Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 6Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 7Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 8Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 9Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year in Recognition of Leading Corporate Citizenship Performance 10Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients 2Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients 3Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients 4
(Date:8/27/2015)... ... ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. Mark Carney announced today that ... on Saturday, August 29, 2015 at the Marriott DTC, 4900 S. Syracuse Street, Denver, ... will present a two part seminar entitled, “How to Thrive as You Age & ...
(Date:8/27/2015)... Michigan (PRWEB) , ... August 27, 2015 , ... On ... returned for the second year as sponsor of the “Music With A Mission” benefit ... raise money for music education programs in the underfunded school districts of Mendon and ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... Mirada, CA (PRWEB) , ... August 27, 2015 , ... ... Agency, into its La Tijera Clinic in Los Angeles. Licensed to practice Chinese Needle ... an emphasis on neuromuscular injuries and diseases. Dr. Priebe also practices in Healthpointe’s La ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor of ... campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing Practice ... the highest level of clinical nursing practice. , “Our vision is to graduate ...
Breaking Medicine News(10 mins):Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2
... Healthy, new heart cells have been generated by animals ... derived from cardiac biopsies or "cardiospheres," according to research ... and Biomedical Sciences. , The research is being ... the American Heart Association in Orlando. , The UB ...
... November 15, 2011 -- A Ben-Gurion University of the ... fertility, producing normal sperm from mouse cells. "This ... who cannot generate sperm and/or pre-pubertal cancer patients at ... and cannot cryopreserve sperm as in adult patients," explains ...
... , MONDAY, Nov. 14 (HealthDay News) -- Researchers have homed ... involved in "chemo brain," the memory problems and other impairments ... to research in the November issue of the Archives ... involved in planning, attention and memory performance were less robust ...
... TUESDAY, Nov. 15 (HealthDay News) -- Patients with cardiovascular disease ... help lower their cholesterol get no additional clinical benefit, a ... HDL cholesterol -- the good cholesterol -- and decrease triglycerides, ... reduce the risk of heart attack, stroke or death, the ...
... Among patients who experienced an ischemic stroke, systolic blood ... than 140 mm Hg, were associated with an increased risk ... November 16 issue of JAMA , a theme issue ... to coincide with the American Heart Association Scientific Sessions. ...
... collect ,near real-time, data about whether people are having ... received the 2009-10 swine flu vaccination in Scotland, researchers ... of safety to future vaccination campaigns. In addition, the ... exposed to the vaccine. The project,s report has just ...
Cached Medicine News:Health News:New heart cells increase by 30 percent after stem cell infusion 2Health News:Breast Cancer Chemo Tied to Memory Troubles 2Health News:Breast Cancer Chemo Tied to Memory Troubles 3Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3Health News:Study evaluates 'normal range' systolic bp levels after ischemic stroke and risk of recurrent stroke 2Health News:New hi-tech survey accelerates collection of vaccination data 2
Provides a perfect ring reference to the corneal surface, most useful for the wound closure evaluation. Shaft angled 35 degrees. Round knurled handle with dull finish....
...
Stainless steel tray for sterilizing instruments....
For sterilizing, carrying and storage of a Storz diamond knife and barrel gauge....
Medicine Products: